临床医学
臨床醫學
림상의학
CLINICAL MEDICINE
2010年
8期
21-23
,共3页
郑小军%刘娟%李会仓%张国栋
鄭小軍%劉娟%李會倉%張國棟
정소군%류연%리회창%장국동
脑卒中%抑郁%黛力新%阿米替林
腦卒中%抑鬱%黛力新%阿米替林
뇌졸중%억욱%대력신%아미체림
Stroke%Depression%Deanxit%Amitriptyline
目的 探讨黛力新与阿米替林治疗脑卒中后抑郁的临床疗效及安全性和对神经功能康复的影响.方法 将80例脑卒中后抑郁患者随机分为黛力新组40例和阿米替林组40例.在治疗脑卒中的基础上,黛力新组口服黛力新治疗,早中各服用1片,阿米替林组服用阿米替林(中、晚) 50～150 mg,疗程为6周.于服药治疗前及服药后2、6周末采用汉密尔顿抑郁量表和TESS量表评定抑郁疗效及不良反应,采用爱丁堡-斯堪的那维亚卒中量表评定神经功能缺损的程度.结果 治疗6周末,黛力新组及阿米替林组显效率分别为85.0%和65.0%,有效率分别为95.0%和77.5%,神经功能康复率分别为87.6%和83.8%.汉密尔顿抑郁量表评分,黛力新组治疗2周末及6周末均较治疗前明显下降(P<0.01),阿米替林组较治疗前亦明显下降(P<0.05).爱丁堡-斯堪的那维亚卒中量表评分两组治疗6周末均较治疗前均明显下降(P<0.01).两组不良反应比较差异有统计学意义(P<0.05),黛力新组不良反应轻微.结论 黛力新组治疗卒中后抑郁与阿米替林组疗效相当,起效快,安全性高,不良反应轻微,依从性好,加速患者神经功能的康复.
目的 探討黛力新與阿米替林治療腦卒中後抑鬱的臨床療效及安全性和對神經功能康複的影響.方法 將80例腦卒中後抑鬱患者隨機分為黛力新組40例和阿米替林組40例.在治療腦卒中的基礎上,黛力新組口服黛力新治療,早中各服用1片,阿米替林組服用阿米替林(中、晚) 50～150 mg,療程為6週.于服藥治療前及服藥後2、6週末採用漢密爾頓抑鬱量錶和TESS量錶評定抑鬱療效及不良反應,採用愛丁堡-斯堪的那維亞卒中量錶評定神經功能缺損的程度.結果 治療6週末,黛力新組及阿米替林組顯效率分彆為85.0%和65.0%,有效率分彆為95.0%和77.5%,神經功能康複率分彆為87.6%和83.8%.漢密爾頓抑鬱量錶評分,黛力新組治療2週末及6週末均較治療前明顯下降(P<0.01),阿米替林組較治療前亦明顯下降(P<0.05).愛丁堡-斯堪的那維亞卒中量錶評分兩組治療6週末均較治療前均明顯下降(P<0.01).兩組不良反應比較差異有統計學意義(P<0.05),黛力新組不良反應輕微.結論 黛力新組治療卒中後抑鬱與阿米替林組療效相噹,起效快,安全性高,不良反應輕微,依從性好,加速患者神經功能的康複.
목적 탐토대력신여아미체림치료뇌졸중후억욱적림상료효급안전성화대신경공능강복적영향.방법 장80례뇌졸중후억욱환자수궤분위대력신조40례화아미체림조40례.재치료뇌졸중적기출상,대력신조구복대력신치료,조중각복용1편,아미체림조복용아미체림(중、만) 50～150 mg,료정위6주.우복약치료전급복약후2、6주말채용한밀이돈억욱량표화TESS량표평정억욱료효급불량반응,채용애정보-사감적나유아졸중량표평정신경공능결손적정도.결과 치료6주말,대력신조급아미체림조현효솔분별위85.0%화65.0%,유효솔분별위95.0%화77.5%,신경공능강복솔분별위87.6%화83.8%.한밀이돈억욱량표평분,대력신조치료2주말급6주말균교치료전명현하강(P<0.01),아미체림조교치료전역명현하강(P<0.05).애정보-사감적나유아졸중량표평분량조치료6주말균교치료전균명현하강(P<0.01).량조불량반응비교차이유통계학의의(P<0.05),대력신조불량반응경미.결론 대력신조치료졸중후억욱여아미체림조료효상당,기효쾌,안전성고,불량반응경미,의종성호,가속환자신경공능적강복.
Objective To explore the curative effect of deanxit and amitriptyline in treating post stroke depression (PSD) and alleviating neurologic impairment. Methods Eighty PSD cases were randomized into deanxit and amitriptyline group, with 40 cases in each group. Two deanxit tablets were adopted for cases in the deanxit group, twice a day. And amitriptyline with the dose ranging from 50 mg to 150 mg was adopted for cases in the amitriptyline group. The clinical efficacy of the two groups were evaluated by using Hamilton rating scale for depression (HAMD) before treatment and the 2nd, 6th week after. Additionally, the treatment emergent symptom scale (TESS) was adopted to evaluate the adverse reactions in the two groups, and the Edinburgh-Scandinavia stroke scale (MESSS) was applied to assess the neurologic impairment. Results Both deanxit and amitriptyline can help relieve the symptoms of PSD patients. In deanxit and amitriptyline group, the significantly effective rate were 85% and 65%,the effective rate were 95.0% and 77.5%, and neurologic impairment recovery rate were 87.6% and 83.8% (P<0.01), respectively. Adverse reactions incident in deanxit group was lower than that in amitriptyline group (P<0.05). Conclusion Compared with amitriptyline, deanxit can definitely benefit PSD patients and improve the neurologic function, while the adverse reactions of it is milder.
